LeapFinancial | $3,500,000 | (Dec 20, 2024)
TG0 | $5,619,170 | (Dec 20, 2024)
Mindgard | $8,000,000 | (Dec 20, 2024)
Prolocor
United States
- Philadelphia, PA
- 01/03/2024
- Unknown
- $1,700,000
There are 50 million people living with chronic coronary artery disease in the U.S., Europe, and Japan. Of these, over 2 million suffer from acute coronary syndrome every year. In each case, the doctor and patient must decide whether to use more powerful therapy to prevent thrombosis – increasing the risk of bleeding – or less intensive therapy – reducing bleeding risk at the expense of more thrombotic events such as heart attack, stroke, and cardiovascular death.
Prolocor’s precision tool will guide treatment decisions, effectively matching the intensity of therapy with the risk of events. Founded by a team that deeply understands thrombosis and cardiovascular disease, Prolocor is building its strategy around platelet FcγRIIa and embarking on a journey to commercialize an innovative precision diagnostic test that quantifies FcγRIIa on the surface of platelets.
- Industry Biotechnology Research
- Website https://www.prolocor.com/
- LinkedIn https://www.linkedin.com/company/prolocor/
Related People
Pete DiBattisteFounder
United States -
Philadelphia, Pennsylvania
Specialties: Cardiovascular Disease
Drug Development
ŌURA | $200,000,000 | (Dec 20, 2024)
Buildpeer | $2,500,000 | (Dec 20, 2024)
Embeddable | $6,238,050 | (Dec 20, 2024)
Tenor | $5,400,000 | (Dec 20, 2024)
SOTELIX Endoscopy | $1,700,000 | (Dec 20, 2024)
Double(US) | $3,900,000 | (Dec 20, 2024)
Hauler Hero | $10,000,000 | (Dec 20, 2024)
TripSuite | $5,000,000 | (Dec 20, 2024)
Seekho | $8,000,000 | (Dec 19, 2024)